INO vs PGEN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

PGEN is the larger of the two ($1.52B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 0.98). INO is the smaller challenger ($327.56M), also expected to post a loss next year: more room to run, but more to prove. If you believe in growth, INO fits: analysts expect its revenue to rise 23913% next year, against 84% for PGEN. If you believe PGEN's main driver (Papzimeos launch ramp) pays off sooner, PGEN fits.

INO vs PGEN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricINOPGENWhat it tells you
Market cap$327.56M$1.52BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-58.29-19.27Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.730.98Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range55% of range20% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Before you buy: how INO and PGEN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. INO and PGEN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined INO and PGEN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Inovio Pharmaceuticals (INO) do?

Inovio Pharmaceuticals is a biotechnology company built around a DNA medicines platform. The idea is to design small circular DNA molecules, called plasmids, that instruct a patient's own cells to produce specific proteins that target disease, and to deliver those plasmids using Inovio's proprietary CELLECTRA device rather than viral vectors or lipid nanoparticles. The company's first product is VOCERYQ (INO-3107), an immunotherapy for recurrent respiratory papillomatosis (RRP), a rare condition in which HPV-driven benign tumors recur in the airway and often require repeated surgeries. Inovio's broader pipeline has historically centered on HPV-related diseases, including head and neck cancer (INO-3112) and cervical dysplasia (VGX-3100, whose US development was discontinued in 2023 while a partner pursues it in China), and it is seeking partners for a DNA-encoded protein platform aimed at rare diseases such as hemophilia A, Fabry disease and hypophosphatasia.

Full INO guide

What does Precigen (PGEN) do?

Precigen, Inc. is a Maryland-based biopharmaceutical company that develops precision medicines using its proprietary gene- and cell-therapy platforms, most notably the AdenoVerse gorilla-adenovector system, which the FDA has granted platform technology designation. For years it was a clinical-stage, cash-burning research company (formerly Intrexon), but in August 2025 it earned full FDA approval for Papzimeos (zopapogene imadenovec, formerly PRGN-2012), the first approved immunotherapy for recurrent respiratory papillomatosis, a rare disease caused by HPV 6 and 11 in which benign tumors recur in the airway and typically require repeated surgeries. Papzimeos is given as four subcutaneous injections over roughly 12 weeks and is designed to trigger an immune response against HPV-infected cells, and it carries FDA market exclusivity through August 14, 2032. Precigen also runs Exemplar, a small research-models and services business.

Full PGEN guide

INO vs PGEN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • INO drivers: VOCERYQ approval and launch in RRP; DNA medicines platform validation.
  • PGEN drivers: Papzimeos launch ramp; From break-even target to profit.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk has moved from approval to execution: VOCERYQ is approved under the accelerated pathway, so continued approval depends on a confirmatory trial whose protocol is still being agreed with the FDA, and a weak launch against Precigen's Papzimeos could leave revenue far below the roughly $84 million analysts expect for 2027. For PGEN, pGEN is a single-product company, so any Papzimeos setback (slower uptake, reimbursement friction, safety signals, or manufacturing issues) would hit the whole thesis at once.

INO or PGEN: which should you pick?

If the story you believe is INO's (VOCERYQ approval and launch in RRP), INO is the more direct way to own it; if it is PGEN's (Papzimeos launch ramp), PGEN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the INO and PGEN guides.

INO vs PGEN: the full fundamentals

INO. Standard valuation multiples do not apply here: Inovio is unprofitable and has not yet booked product sales, so P/E is meaningless and P/S above 1,000 says nothing useful. At about $327 million in market cap, roughly triple its pre-approval value as the price rose and the share count grew, the stock prices in a launch but not a large one, against consensus 2027 revenue near $84 million. Verify the latest cash position, share count, and launch progress before acting, as they can change within days.

PGEN. Precigen moved from commercial launch to two profitable quarters and positive operating cash flow in just over a year, with Q3 2026 revenue of about $74.1 million and net income of about $35.8 million. After a 42% three-month drop the stock trades near 10 times trailing sales and about 38 times trailing earnings, far less stretched than in October, and it still trades on forward launch expectations: consensus revenue of about $240 million in 2026 and $442 million in 2027. The three analysts tracked by Yahoo Finance hold a mean target near $13.67, well above the $4.22 price.

Headline figures (approximate, November 2026): INO shows revenue (ttm) ~$0.3 million (collaborations); VOCERYQ sales expected from 2027, net income (ttm) ~-$71 million loss, q3 2026 net loss ~$49.2 million (includes a ~$26.9M non-cash warrant loss), cash and short-term investments ~$48.4 million at Sept 30, 2026, plus ~$80.5M net raised in November; PGEN shows stock price ~$4.22 (Nov 20, 2026); YTD -1%, 1-month -32%, market cap ~$1.5B, revenue (q3 2026 / ttm) ~$74.1M / ~$157M, papzimeos revenue (q3 2026) ~$72.9M, +37% QoQ (~$151M launch to date).

The bottom line: INO vs PGEN

INO and PGEN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined INO and PGEN exposure against your real portfolio. It is not an investment adviser.

Wondering how INO or PGEN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Inovio Pharmaceuticals

Ask Walnut's AI anything about INO and see how it fits what you own.

FAQ

What is the difference between INO and PGEN?

+

Inovio Pharmaceuticals is a biotechnology company built around a DNA medicines platform. Precigen, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is INO or PGEN the better stock?

+

Neither is universally better. PGEN is the larger incumbent; INO is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, INO or PGEN?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both INO and PGEN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of INO vs PGEN?

+

INO: The dominant risk has moved from approval to execution: VOCERYQ is approved under the accelerated pathway, so continued approval depends on a confirmatory trial whose protocol is still being agreed with the FDA, and a weak launch against Precigen's Papzimeos could leave revenue far below the roughly $84 million analysts expect for 2027. As an early commercial biotech, Inovio has no product sales yet, is not profitable, and has a history of operating losses, so it relies on issuing new stock to survive; the November 2026 offering is the latest example, and dilution can erode per-share value even when news is good. The company has done multiple reverse stock splits over time. Reported results swing with non-cash warrant revaluations (a $26.9 million loss in Q3 2026), which can make quarterly losses look larger or smaller than operations. Commercial success in a rare disease requires reimbursement, adoption, and manufacturing execution, and the label carries warnings on injection site reactions and on use near implanted cardiac devices or metal implants. After a near-doubling in a month, the stock is also exposed to sharp reversals. Broader risks include competition, dependence on the CELLECTRA platform, and the high failure rate of drug development. PGEN: PGEN is a single-product company, so any Papzimeos setback (slower uptake, reimbursement friction, safety signals, or manufacturing issues) would hit the whole thesis at once. The roughly $1.5 billion market cap still sits well ahead of trailing revenue of about $157 million, so the valuation embeds launch assumptions that leave little margin for disappointment; the shares fell about 32% in the month to November 20, 2026 and about 42% over three months despite a quarter of 37% sequential product growth, which shows how quickly sentiment can swing. Competition is moving closer: on the Q3 call management addressed the prospective launch of Inovio's INO-3107 and said it had planned for competition from the outset, citing payer policies, physician experience and treatment-site capabilities. Cash and investments were about $51 million at September 30, 2026 against about $98.6 million of debt, so a stall in the ramp could still require dilutive financing. The RRP niche, while high-need, is small, and the stock has historically been volatile and heavily shorted.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell INO or PGEN; figures are approximate and dated (as of November 2026). Verify current data before investing.